297 related articles for article (PubMed ID: 18922108)
1. mTOR inhibitors in the treatment of cancer.
Fasolo A; Sessa C
Expert Opin Investig Drugs; 2008 Nov; 17(11):1717-34. PubMed ID: 18922108
[TBL] [Abstract][Full Text] [Related]
2. Deforolimus (AP23573) a novel mTOR inhibitor in clinical development.
Mita M; Sankhala K; Abdel-Karim I; Mita A; Giles F
Expert Opin Investig Drugs; 2008 Dec; 17(12):1947-54. PubMed ID: 19012509
[TBL] [Abstract][Full Text] [Related]
3. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway.
Smolewski P
Anticancer Drugs; 2006 Jun; 17(5):487-94. PubMed ID: 16702804
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic targets: MTOR and related pathways.
Dancey JE
Cancer Biol Ther; 2006 Sep; 5(9):1065-73. PubMed ID: 16969122
[TBL] [Abstract][Full Text] [Related]
5. Current and future directions in mammalian target of rapamycin inhibitors development.
Fasolo A; Sessa C
Expert Opin Investig Drugs; 2011 Mar; 20(3):381-94. PubMed ID: 21299441
[TBL] [Abstract][Full Text] [Related]
6. mTOR signalling in human cancer.
Albanell J; Dalmases A; Rovira A; Rojo F
Clin Transl Oncol; 2007 Aug; 9(8):484-93. PubMed ID: 17720651
[TBL] [Abstract][Full Text] [Related]
7. The applicability of mTOR inhibition in solid tumors.
Konings IR; Verweij J; Wiemer EA; Sleijfer S
Curr Cancer Drug Targets; 2009 May; 9(3):439-50. PubMed ID: 19442061
[TBL] [Abstract][Full Text] [Related]
8. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of the mammalian target of rapamycin.
Dancey JE
Expert Opin Investig Drugs; 2005 Mar; 14(3):313-28. PubMed ID: 15833062
[TBL] [Abstract][Full Text] [Related]
10. Potential of mTOR inhibitors as therapeutic agents in hematological malignancies.
Sankhala K; Giles FJ
Expert Rev Hematol; 2009 Aug; 2(4):399-414. PubMed ID: 21082945
[TBL] [Abstract][Full Text] [Related]
11. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
Grzybowska-Izydorczyk O; Smolewski P
Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
[TBL] [Abstract][Full Text] [Related]
12. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
13. Targeting mTOR pathways in human malignancies.
Fasolo A; Sessa C
Curr Pharm Des; 2012; 18(19):2766-77. PubMed ID: 22475451
[TBL] [Abstract][Full Text] [Related]
14. Targeting the mTOR pathway using deforolimus in cancer therapy.
Mahalingam D; Sankhala K; Mita A; Giles FJ; Mita MM
Future Oncol; 2009 Apr; 5(3):291-303. PubMed ID: 19374536
[TBL] [Abstract][Full Text] [Related]
15. PI3K/Akt/mTOR pathway as a target for cancer therapy.
Morgensztern D; McLeod HL
Anticancer Drugs; 2005 Sep; 16(8):797-803. PubMed ID: 16096426
[TBL] [Abstract][Full Text] [Related]
16. NCCN Task Force Report: mTOR inhibition in solid tumors.
Figlin RA; Brown E; Armstrong AJ; Akerley W; Benson AB; Burstein HJ; Ettinger DS; Febbo PG; Fury MG; Hudes GR; Kies MS; Kwak EL; Morgan RJ; Mortimer J; Reckamp K; Venook AP; Worden F; Yen Y
J Natl Compr Canc Netw; 2008 Sep; 6 Suppl 5():S1-20; quiz S21-2. PubMed ID: 18926092
[TBL] [Abstract][Full Text] [Related]
17. Dual mTOR/PI3K inhibitor NVP‑BEZ235 arrests colorectal cancer cell growth and displays differential inhibition of 4E‑BP1.
Alqurashi N; Hashimi SM; Alowaidi F; Ivanovski S; Wei MQ
Oncol Rep; 2018 Aug; 40(2):1083-1092. PubMed ID: 29845289
[TBL] [Abstract][Full Text] [Related]
18. The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy.
Janus A; Robak T; Smolewski P
Cell Mol Biol Lett; 2005; 10(3):479-98. PubMed ID: 16217558
[TBL] [Abstract][Full Text] [Related]
19. ATP-competitive inhibitors of mTOR: an update.
Schenone S; Brullo C; Musumeci F; Radi M; Botta M
Curr Med Chem; 2011; 18(20):2995-3014. PubMed ID: 21651476
[TBL] [Abstract][Full Text] [Related]
20. Clinical development of mTOR inhibitors: a focus on lymphoma.
Smith SM
Rev Recent Clin Trials; 2007 May; 2(2):103-10. PubMed ID: 18473994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
